Transmyocardial revascularisation (TMR) mortality data go to FDA:
This article was originally published in Clinica
PLC Systems has submitted data from two recent Heart Laser trials to the US FDA in support of its PMA application. In the most recent study, laser revascularisation cut six month mortality by 63% compared with medical therapy in 100 patients with untreatable coronary artery disease and grade III or IV angina. Six-month mortality was 6% in laser patients compared with 16% in the medically treated patients
You may also be interested in...
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway